Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human anti-tetanus toxin monoclonal antibody in healthy volunteers
NCT07149454Phase 1Enrolling by invitation
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- Aug 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tetanus (5 arms), sponsored by Lanzhou Institute of Biological Products Co., Ltd. Primary endpoints: Adverse Events at 105 days, Serious Adverse Events at 105 days and 5 more. Started Aug 2025; status: enrolling by invitation.
02
Conditions
Tetanus
Beyond the preview
Go deeper on NCT07149454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149454.